1620 – Blood lipid spectrum changes in first-episode schizophrenia patients treated with risperidone and haloperidol

Abstract

The aimComparative study of the blood lipid spectrum changes in first-episode schizophrenia patients treated with risperidone and haloperidol.Materials and methods68 patients with first-episode schizophrenia (average age 24,9 years) and 20 age-matched normal controls were investigated. All patients had PANSS total score not less than 80 points. The patients were divided in two groups of 34 persons in each group: treated with haloperidol and risperidone. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), non-high-density lipoprotein cholesterol (non-HDL), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), lipoprotein(a) (Lp(a)) levels were determined in serum before treatment and after 8 weeks of therapy.ResultsBefore the treatment TC, LDL, non-HDL, apoB, Lp(a) levels were authentically higher, but HDL level was lower. After treatment with risperidone and haloperidol HDL and apoA1 levels were increased. In patient group treated with risperidone TC, LDL, non-HDL, apoB, Lp(a) levels did not authentically change after 8 weeks. After treatment with haloperidol TC, LDL, non- HDL, apoB, Lp(a) levels were decreased.ConclusionsChanges of blood lipid spectrum in first-episode schizophrenia patients were discovered. It was established changes of lipid spectrum in patients treated with risperidone and haloperidol. Haloperidol was noticed to positively influence on blood lipid spectrum in first-episode schizophrenia patients.

Association between cognitive impairment and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia

“…ApoA1 is the main protein component of HDL, and a biomarker of cardiovascular disease [31], while ApoB is the main protein including plasma chylomicrons, verylow-density lipoprotein (VLDL) and LDL [32], which can be used as a biomarker of schizophrenia [33]. On the one hand, numerous studies have observed the mixed changes in ApoA1 and ApoB levels in patients with schizophrenia, such as an increase in ApoA1 [31,34,35] or ApoB [33,36,37] and reduction of ApoA1 [37,38], or ApoB [35]. On the other hand, ApoA1 and ApoB levels may be associated with cognitive decline [39,40], which has been indirectly verified by a number of mouse experiments [41,42].…”

Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia

“…The median ApoA1 and ApoB levels of health controls were 1.19 g/L and 0.86 g/L in the Africans, 1.15 g/L and 0.98 g/L in the Arabs, 1.23 g/L and 0.83 g/L in the Chinese, 1.26 g/L and 0.95 g/L in the Europeans, 1.18 g/L and 0.95 g/L in the Latin Americans, 1.07 g/L and 0.92 g/L in the South Asians, and 1.29 g/L and 0.96 g/L in the Southeast Asians, respectively [ 34 ]. A large number of studies have observed changes in the levels of ApoA1 and ApoB in patients with schizophrenia, with mixed results, such as elevated ApoA1 [ 31 , 35 , 36 ] or ApoB [ 37 – 39 ], which can be used as biomarkers of schizophrenia [ 39 ] as well as decreased ApoA1 [ 38 , 40 ] or ApoB [ 36 ]. In addition, ApoE gene polymorphism may affect the expression levels of ApoA1 and ApoB [ 41 – 43 ].…”